Schematic diagram of the SPP1+ macrophage model in CRC. (IMAGE)
Caption
(A) Classification of macrophage subsets in CRC, including FCN1+, C1QC+, SPP1+, and MKI67+ macrophages, defined by their core features of inflammation, phagocytosis, malignancy, and proliferation, respectively. (B) Model of the developmental trajectory of monocyte/macrophage lineages in different sample types from CRLM and HCC patients. This model shows the cell origin and tissue distribution of SPP1+ macrophages. (C) The number and proportion of SPP1+ macrophages increased during CRC occurrence, progression, and metastasis, making them a marker of CRC malignancy. Blue, yellow, and red dots represent the numbers of all immune cells, all macrophages, and SPP1+ macrophages in the sample, respectively. (D) SPP1+ macrophages had distinct signatures compared with other macrophages (left). Red: signature specifically elevated in SPP1+ macrophages. Yellow: signature elevated in SPP1+ macrophages compared with C1QC+ macrophages. Blue: signature decreased in SPP1+ macrophages compared with C1QC+ macrophages. The right shows the crosstalk between SPP1+ macrophages and other cell subsets through the SPP1 protein. (E) Patients with a high proportion of SPP1+ macrophages have a worse prognosis, along with signatures related to genome instability and mutations. Immunotherapy has the potential to improve outcomes in patients with a high proportion of SPP1+ macrophages, whereas targeting CSF1R is less effective. SPP1, secreted phosphoprotein 1; CSF1R, colony-stimulating factor 1 receptor; CRC, colorectal cancer; CRLM, colorectal cancer liver metastases; HCC, hepatocellular carcinoma; C1QC, complement C1q C chain.
Credit
Genes & Diseases
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND